Sarepta Therapeutics (SRPT) PT Lowered to $200 at RBC Capital
Tweet
Share
E-mailGet Alerts SRPT Hot Sheet
Price: $18.18 +0.44%
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 1 | Down: 4 | New: 5
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 1 | Down: 4 | New: 5
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $200.00 (from $203.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Citi Downgrades Lend Lease Group (LLC:AU) (LLESY) to Neutral
- Aurizon Holdings (AZJ:AU) (QRNNF) PT Lowered to AUD3.90 at Citi
- Misumi Group (9962:JP) PT Raised to JPY5,500 at Citi
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
